Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α
- 30 August 2002
- journal article
- clinical trial
- Published by Springer Nature in Leukemia
- Vol. 16 (9) , 1579-1583
- https://doi.org/10.1038/sj.leu.2402680
Abstract
Leukemia is one of the leading journals in hematology and oncology. It is published monthly and covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance.Keywords
This publication has 32 references indexed in Scilit:
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Chronic Myeloid Leukemia: A Minimalistic View of Post-Therapeutic MonitoringThe Journal of Molecular Diagnostics, 2002
- Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 casesLeukemia, 2002
- Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic respondersBlood, 2001
- Quality assurance in RT-PCR-based BCR/ABL diagnostics – results of an interlaboratory test and a standardization approachLeukemia, 2000
- Autologous Transplantation of In Vivo Purged PBSC in CMLCancer Genetics and Cytogenetics, 2000
- Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCRLeukemia, 1999
- Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a ‘real time’ quantitative RT-PCR assayLeukemia, 1999
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon α therapy?Leukemia, 1998